378 related articles for article (PubMed ID: 17493854)
1. Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design.
Schiewe AJ; Haworth IS
J Mol Graph Model; 2007 Oct; 26(3):667-75. PubMed ID: 17493854
[TBL] [Abstract][Full Text] [Related]
2. Structural prediction of peptides binding to MHC class I molecules.
Bui HH; Schiewe AJ; von Grafenstein H; Haworth IS
Proteins; 2006 Apr; 63(1):43-52. PubMed ID: 16447245
[TBL] [Abstract][Full Text] [Related]
3. Ranking potential binding peptides to MHC molecules by a computational threading approach.
Altuvia Y; Schueler O; Margalit H
J Mol Biol; 1995 Jun; 249(2):244-50. PubMed ID: 7540211
[TBL] [Abstract][Full Text] [Related]
4. Candidate epitope identification using peptide property models: application to cancer immunotherapy.
Sung MH; Simon R
Methods; 2004 Dec; 34(4):460-7. PubMed ID: 15542372
[TBL] [Abstract][Full Text] [Related]
5. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
Douat-Casassus C; Marchand-Geneste N; Diez E; Gervois N; Jotereau F; Quideau S
J Med Chem; 2007 Apr; 50(7):1598-609. PubMed ID: 17328535
[TBL] [Abstract][Full Text] [Related]
6. A structure-based approach for prediction of MHC-binding peptides.
Altuvia Y; Margalit H
Methods; 2004 Dec; 34(4):454-9. PubMed ID: 15542371
[TBL] [Abstract][Full Text] [Related]
7. Class I MHC-peptide interaction: structural and functional aspects.
Ruppert J; Kubo RT; Sidney J; Grey HM; Sette A
Behring Inst Mitt; 1994 Jul; (94):48-60. PubMed ID: 7998914
[TBL] [Abstract][Full Text] [Related]
8. Predicting peptide binding to Major Histocompatibility Complex molecules.
Liao WW; Arthur JW
Autoimmun Rev; 2011 Jun; 10(8):469-73. PubMed ID: 21333759
[TBL] [Abstract][Full Text] [Related]
9. POPI: predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties.
Tung CW; Ho SY
Bioinformatics; 2007 Apr; 23(8):942-9. PubMed ID: 17384427
[TBL] [Abstract][Full Text] [Related]
10. MAPPP: MHC class I antigenic peptide processing prediction.
Hakenberg J; Nussbaum AK; Schild H; Rammensee HG; Kuttler C; Holzhütter HG; Kloetzel PM; Kaufmann SH; Mollenkopf HJ
Appl Bioinformatics; 2003; 2(3):155-8. PubMed ID: 15130801
[TBL] [Abstract][Full Text] [Related]
11. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.
Parker KC; Bednarek MA; Coligan JE
J Immunol; 1994 Jan; 152(1):163-75. PubMed ID: 8254189
[TBL] [Abstract][Full Text] [Related]
12. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules.
Gomez-Nunez M; Pinilla-Ibarz J; Dao T; May RJ; Pao M; Jaggi JS; Scheinberg DA
Leuk Res; 2006 Oct; 30(10):1293-8. PubMed ID: 16533527
[TBL] [Abstract][Full Text] [Related]
13. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach.
Nielsen M; Lundegaard C; Worning P; Hvid CS; Lamberth K; Buus S; Brunak S; Lund O
Bioinformatics; 2004 Jun; 20(9):1388-97. PubMed ID: 14962912
[TBL] [Abstract][Full Text] [Related]
14. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
15. Structural prediction of peptides bound to MHC class I.
Fagerberg T; Cerottini JC; Michielin O
J Mol Biol; 2006 Feb; 356(2):521-46. PubMed ID: 16368108
[TBL] [Abstract][Full Text] [Related]
16. Differences in MHC class I self peptide repertoires among HLA-A2 subtypes.
Sudo T; Kamikawaji N; Kimura A; Date Y; Savoie CJ; Nakashima H; Furuichi E; Kuhara S; Sasazuki T
J Immunol; 1995 Nov; 155(10):4749-56. PubMed ID: 7594476
[TBL] [Abstract][Full Text] [Related]
17. Ab initio prediction of peptide-MHC binding geometry for diverse class I MHC allotypes.
Bordner AJ; Abagyan R
Proteins; 2006 May; 63(3):512-26. PubMed ID: 16470819
[TBL] [Abstract][Full Text] [Related]
18. Selecting informative data for developing peptide-MHC binding predictors using a query by committee approach.
Christensen JK; Lamberth K; Nielsen M; Lundegaard C; Worning P; Lauemøller SL; Buus S; Brunak S; Lund O
Neural Comput; 2003 Dec; 15(12):2931-42. PubMed ID: 14629874
[TBL] [Abstract][Full Text] [Related]
19. Consensus motifs and peptide ligands of MHC class I molecules.
Falk K; Rötzschke O
Semin Immunol; 1993 Apr; 5(2):81-94. PubMed ID: 7684938
[TBL] [Abstract][Full Text] [Related]
20. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
